Intended for healthcare professionals


NICE U turns to offer olaparib for breast and prostate cancer following discount deal

BMJ 2023 ; 381 doi: (Published 11 April 2023) Cite this as: BMJ 2023;381:p814
  1. Elisabeth Mahase
  1. The BMJ

The National Institute for Health and Care Excellence (NICE) has recommended olaparib for some types of early breast cancer and advanced prostate cancer in new draft guidelines, 1 after previously rejecting it over price. 2 3

The decision to reverse the rejection comes after a deal was negotiated between NHS England and manufacturer AstraZeneca to provide the treatment at a lower price. NICE …

View Full Text

Log in

Log in through your institution


* For online subscription